To provide an overview of contemporary advances in the treatment of metabolic bone diseases, particularly focusing on osteoporosis and related disorders.
Approach:
Overview of Advances: The editorial discusses recent developments in therapies for metabolic bone diseases, emphasizing the multidimensional nature of skeletal medicine.
Pharmacological Strategies: It focuses on pharmacological strategies targeting bone remodeling and mineral metabolism, including established efficacy of zoledronic acid and insights from FGF23 biology.
Role of Sclerostin: The role of sclerostin in bone formation is examined, leading to the development of anti-sclerostin antibodies as a treatment for osteoporosis.
Mineral Metabolism Optimization: The editorial discusses ongoing investigations of vitamin D analogues, including doxercalciferol, and their potential therapeutic value.
Systemic Determinants of Skeletal Health: It highlights the influence of systemic factors, such as gut microbiota and metabolic surgery, on bone health.
Patient-Centered Outcomes: The importance of patient-reported outcomes and chronic disease burden in treatment efficacy is discussed.
Key Findings:
Zoledronic acid has established antifracture efficacy in osteoporosis.
Burosumab is effective for X-linked hypophosphatemia and tumor-induced osteomalacia.
Anti-sclerostin antibodies represent a significant advancement in osteoporosis therapy.
Doxercalciferol shows potential in preventing bone loss over 24 months.
Gut microbiota dysbiosis is linked to osteoporosis, suggesting a gut–bone axis.
Metabolic surgery affects bone turnover and increases fracture risk.
Interpretation:
The studies reflect a shift in bone research towards mechanism-driven interventions, aiming to translate biological advances into clinical strategies.
Limitations:
Challenges remain in determining optimal treatment duration and sequencing of therapies for osteoporosis and related conditions.
Long-term management strategies for certain metabolic bone diseases are not fully defined.
Conclusion:
The editorial underscores the need for continued innovation in metabolic bone disease treatments, integrating insights from various physiological systems.
